Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0310 has been discontinued.
View all Non-selective Ionotropic Glutamate products.(RS)-4-Carboxy-3-hydroxyphenylglycine is a broad spectrum EAA agonist/antagonist.
S-enantiomer also available.
M. Wt | 211.17 |
Formula | C9H9NO5 |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 134052-66-7 |
PubChem ID | 1297 |
InChI Key | GXZSAQLJWLCLOX-UHFFFAOYSA-N |
Smiles | NC(C(O)=O)C1=CC(O)=C(C=C1)C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Watkins et al (1987) Recent advances in the pharmacology of excitatory amino acids. Excitatory Amino Acid Transmission. Eds. Hicks, Lo 19-26
Keywords: (RS)-4-Carboxy-3-hydroxyphenylglycine, (RS)-4-Carboxy-3-hydroxyphenylglycine supplier, Broad, spectrum, EAA, ligand, agonists, antagonists, Glutamate, Ionotropic, Non-Selective, iGluR, Receptors, mGlur, Metabotropic, (RS)-4C3HPG, Non-selective, mGlu, 0310, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for (RS)-4-Carboxy-3-hydroxyphenylglycine.
There are currently no reviews for this product. Be the first to review (RS)-4-Carboxy-3-hydroxyphenylglycine and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.